Advertisement
"We fully intend to continue to market Quasense(TM), our generic versionof Seasonale(R) and will defend this case vigorously," commented Paul Bisaro,Watson's President and Chief Executive Officer.
Advertisement
Watson launched its Quasense(TM) product in September 2006 following theU.S. Food and Drug Administration's final approval of its abbreviated new drugapplication. On September 25, 2007, the U.S. Patent and Trademark Office(PTO) issued to Duramed U.S. Patent No. RE39,861 (the '861 Patent) related toSeasonale(R). On December 13, 2007, Barr filed suit against Watson in theU.S. District Court of New Jersey alleging infringement of the '861 Patentseeking to prevent Watson from further commercializing its Quasense(TM)product.
Forward-Looking Statement
Any statements contained in this press release that refer to future eventsor other non-historical facts are forward-looking statements that reflectWatson's current perspective of existing trends and information as of the dateof this release. Except as expressly required by law, Watson disclaims anyintent or obligation to update these forward-looking statements. Actualresults may differ materially from Watson's current expectations dependingupon a number of factors affecting Watson's business. These factors include,among others, the difficulty of predicting the timing and outcome oflitigation; risks that resolution of patent infringement litigation throughsettlement could result in investigations or actions by private parties orgovernment authorities; the impact of competitive products and pricing; andother risks and uncertainties detailed in Watson's periodic public filingswith the Securities and Exchange Commission, including but not limited toWatson's Annual Report on Form 10-K for the year ended December 31, 2006.
Seasonale(R) is a registered trademark of Duramed Pharmaceuticals, Inc.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)
SOURCE Watson Pharmaceuticals, Inc.
